Shane Pearce, MD
Urology · Spokane, WANPI 1518253988
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 68.1% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $35,886, more than ten times the $840 reported in 2019. Among urology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $256.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$27K
- Janssen Scientific Affairs, LLC$9K
- Janssen Global Services, LLC$500
- KARL Storz Endoscopy-america$400
- Urogen Pharma, Inc.$387
- Ferring Pharmaceuticals Inc.$373
- plus $3K from 27 others
Across 151 payments — averaging $11,591 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$991K
- AstraZeneca$322K
- Merck$292K
- Urogen Pharma, Inc.$144K
What the payments were for
- Consulting fees$21,04553%
- Speaking & faculty fees$11,88030%
- Travel & lodging$2,0075%
- Food & beverage$4,74512%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 43 | $27,103 |
| Janssen Scientific Affairs, LLC | 4 | $8,521 |
| Janssen Global Services, LLC | 1 | $500 |
| KARL Storz Endoscopy-america | 8 | $400 |
| Urogen Pharma, Inc. | 7 | $387 |
| Ferring Pharmaceuticals Inc. | 3 | $373 |
| AbbVie(2 entities) | 17 | $367 |
| Astellas Pharma US Inc | 7 | $227 |
| Photocure Inc | 4 | $196 |
| Sumitomo Pharma America, Inc. | 9 | $178 |
| Rochester Medical Corporation | 7 | $175 |
| Boston Scientific | 2 | $175 |
| Koelis Inc. | 1 | $164 |
| Amgen | 3 | $147 |
| Merck | 6 | $126 |
| Sun Pharmaceutical Industries Inc. | 4 | $112 |
| Dendreon Pharmaceuticals LLC | 4 | $101 |
| Intuitive Surgical | 1 | $95 |
| Pfizer | 4 | $78 |
| Foundation Medicine, Inc. | 1 | $66 |
| Bayer | 3 | $47 |
| Bioprotect Medical, Inc. | 2 | $45 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Coloplast | 2 | $30 |
| Palette Life Sciences, Inc. | 1 | $29 |
| Telix Pharmaceuticals | 1 | $20 |
| Cardinal Health 414 LLC | 1 | $18 |
| Olympus America Inc. | 1 | $15 |
| Immunitybio, Inc. | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,795 in reported general payments places this provider in the 90th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 42 | $574,648 |
| OrgovyxRelugolix | 80 | $201,350 |
| Abiraterone Acetate | 13 | $58,389 |
| MyrbetriqMirabegron | 37 | $24,821 |
| Tamsulosin Hcl | 273 | $2,841 |
| Oxybutynin Chloride ErOxybutynin Chloride | 79 | $1,516 |
| Finasteride | 82 | $846 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $639 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $602 |
| Oxybutynin Chloride | 79 | $507 |
| Ciprofloxacin Hcl | 19 | $317 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 79 | $316 |
| Potassium Chloride | 12 | $293 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $262 |
| Cephalexin | 29 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $227 | $599,46979 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $178 | $201,35080 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $8,521 | $58,38913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Washington.
Other urology in Spokane
- Raymond LanceSpokane$211K
- Evan CarlosSpokane$18K
- Carl WalkerSpokane$10K
- Michael MacciniSpokane$10K
- Levi DetersSpokane$6K
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.